Protein Aggregates Are Recruited to Aggresome by Histone Deacetylase 6 via Unanchored Ubiquitin C Termini

Hui Ouyang, Yousuf O. Ali, Mani Ravichandran, Aiping Dong, Wei Qiu, Farrell MacKenzie, Sirano Dhe-Paganon, Cheryl H. Arrowsmith, and R. Grace Zhai

From the Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada, the Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida 33136, and University Health Network, Toronto, Ontario M5G 2C4, Canada

Background: Misfolded protein aggregates are recruited to the aggresome by a protein complex consisting of histone deacetylase 6 (HDAC6).

Results: The ubiquitin-binding domain (ZnF-UBP) of HDAC6 binds to ubiquitin C termini generated by ataxin-3.

Conclusion: The exposure of ubiquitin C termini within protein aggregates enables HDAC6 recognition.

Significance: This study provides the role of HDAC6 in aggresome formation and suggests a novel ubiquitin-mediated signaling pathway.

The aggresome pathway is activated when proteasomal clearance of misfolded proteins is hindered. Misfolded polyubiquitinated protein aggregates are recruited and transported to the aggresome via the microtubule network by a protein complex consisting of histone deacetylase 6 (HDAC6) and the dynein motor complex. The current model suggests that HDAC6 recognizes protein aggregates by binding directly to polyubiquitinated proteins. Here, we show that there are substantial amounts of unanchored ubiquitin in protein aggregates with solvent-accessible C termini. The ubiquitin-binding domain (ZnF-UBP) of HDAC6 binds exclusively to the unanchored C-terminal diglycine motif of ubiquitin instead of conjugated polyubiquitin. The unanchored ubiquitin C termini in the aggregates are generated in situ by aggregate-associated deubiquitinase ataxin-3. These results provide structural and mechanistic bases for the role of HDAC6 in aggresome formation and further suggest a novel ubiquitin-mediated signaling pathway, where the exposure of ubiquitin C termini within protein aggregates enables HDAC6 recognition and transport to the aggresome.

The ubiquitin proteasome pathway is the primary “quality control” mechanism that cells use to break down misfolded proteins, which are polyubiquitinated in preparation for degradation (1, 2). When proteasomal functions are disrupted or overloaded, misfolded proteins cannot be cleared and protein aggregation ensues (3). In such cases, the aggresome pathway is activated, and cytoplasmic protein aggregates are transported to the microtubule organizing center, where aggresomes are formed (3). Aggresomes are dynamic structures that can recruit various chaperones and transporters to aid in the disposal of aggregated proteins (4).

Aggresome formation is often considered a cytoprotective response, allowing for sequestration of potentially toxic misfolded proteins and promoting their clearance by autophagy (5). Accumulating evidence suggests an important role for HDAC6 in the transport and clearance of misfolded proteins by favoring the formation of aggresomes and activating autophagy (6, 7). HDAC6 modulates a wide range of cellular activities through distinct interactions with cellular components including tubulin, cortactin, HSP90, and other proteins and protein complexes (8, 9). In the aggresome pathway, HDAC6 plays the key role of gathering scattered polyubiquitinated protein aggregates and transporting them to aggresomes via microtubule tracts. HDAC6 has been shown to bind polyubiquitinated aggregates and dynactin/p150Glued, a component of the dynein motor complex, bridging the ubiquitinated proteins to the dynein motors and promoting transport of the cargo toward the microtubule organizing center to enable aggresome formation (10, 11).

HDAC6 is thought to interact with aggregated proteins through its ZnF-UBP domain (11), a domain typically found in...
HDAC6RecruitsProteinAggregatesviaUbiquitinCTermini
debiquitinasescapableofbindingtheunanchoredubiquitinC
terminuswithhighaffinityandspecificity(12,13).However,in
polyubiquitinatedproteins,ubiquitinmoietiesareconjugated
to target polypeptide chains through C-terminal diglycine
motifs(14)andserveasmoleculartagsthatareusuallyrecog-
nized by downstream proteins through its globular surface,
often through a hydrophobic area around Ile-44 (15,16).
Therefore,itisdifficult toreconcilewhereHDAC6canpoten-
tially bind polyubiquitin chains of aggregated proteins through
itsZnF-UBP domain.

Heredemonstrate themolecular mechanism of how scat-
tered protein aggregates are recognized by HDAC6. First, we
showthattheHDAC6ZnF-UBP domaininteractsdirectlywith
protein aggregates using immunoprecipitation approaches.
Then we solved the crystal structure of the ZnF-UBP domain of
HDAC6 and its complexes with either full-length ubiquitin or a
ubiquitin-C-terminal peptide. This structural and biochemical
analysis revealed that an intact and unanchored (noncovalently
modified) ubiquitin C-terminal diglycine motif is necessary and
sufficient for binding to HDAC6 ZnF-UBP. Second, we show
that such unanchored ubiquitin C termini are present abund-
antly in aggresomes. It is the solvent-accessible ubiquitin C
termi nthattagprotein aggregates for HDAC6recognition.
These unanchored C termini are generated by the aggregate-
related deubiquitinasen, ataxin-3, which cleaves (poly)ubiq-
quitin moieties in polyubiquitinated proteins to expose their C-
terminal diglycine motifs for HDAC6 binding and subsec-
tuent transport to the aggresome. Our work thus offers a crit-
ical piece of the mechanism underlying how HDAC6 recruits
protein aggregates.

EXPERIMENTAL PROCEDURES

Materials—Purchased protein reagents used in various
experiments included: HDAC6 (Biomol), ubiquitin (Boston
Biochem), tetraubiquitin (Boston Biochem), and ubiquitin-
AFC (7-amino-4-trifluoromethylcoumarin) (Boston Biochem).
Peptide RLRGG was synthesized at the Tufts University Core
Facility (Boston).

Antibodies used in various experiments included: anti-GFP
antibody (product number A11212; Invitrogen), anti-ataxin3
antibody (product #MABN37; Millipore), anti-HDAC6 anti-
bod y (product number AB12173; Abcam), anti-C-terminal
ubiquitin antibody (product number 04-454; Millipore), anti-
N-terminal ubiquitin antibody (product number AP1228a;
Abgent), anti-USP5 antibody (product number AP2134a;
Abgent), anti-USP13 antibody (product number AB99421;
Abcam), Alexa 555- or Alexa 647-conjugated secondary anti-
bodies (Molecular Probes); and infrared dye-conjugated sec-
ondary antibodies, IR700 and IR800 (LI-COR Biosciences).

Cloning, Protein Expression, Purification, and Crystallization—
ZnF-UBP domains of HDAC6 (1109–1215) and USP5 (171–
290) were amplified by PCR from the Mammalian Gene Collec-
tion clone (with GenBankTM accession numbers BC013737 and
BC004889, respectively) and subcloned into a modified
pET28a-LIC vector. The mutants were prepared by the QuiKChange (Stratagene) site-directed mutagenesis method.
The recombinant proteins were overexpressed in LB medium
as N-terminal His6-tagged proteins at 15 °C using Escherichia
coli strain BL21 (DE3) codon plus RIL (Stratagene). For purifi-
cation, the cells were lysed by passing through a Microfluidizer
(Microfluidics Corporation) at 18,000 p.s.i. The purification
procedure comprised of two steps: affinity chromatography on
a Ni-NTA column (Qiagen) and gel filtration on a Superdex 75
column (26/60; GE Healthcare). The His tag was cleaved with
thrombin after the affinity column step while dialyzing against
20 mM Tris, pH 8.0, 0.15 M NaCl, and 1 mM TCEP (Buffer A).
Crystals of the HDAC6 ZnF-UBP domain were grown at 18 °C
using the sitting drop method by mixing equal volumes of 3.5 M
sodium formate, 100 mM Bis-Tris, pH 7.0, and 15 mg/ml protein.
Crystals of the HDAC6 ZnF-UBP (15 mg/ml) and monou-
biquitin (15 mg/ml) were grown at 28 °C using the sitting drop
method by mixing with equal volumes of 15% PEG 3350, 0.1 M
(NH4)2SO4, 0.1 M Bis-Tris, pH 5.6. Crystals of the HDAC6 ZnF-
UBP domain and RLRGG complex were grown at 18 °C using
the hanging drop method by mixing equal volumes of 20% PEG3350, 0.2 M CaCl2, 0.1 M Bis-Tris, pH 7.0, and 15 mg/ml
protein solution with 3 mM peptide.

Data Collection and Structure Determination—The single
wavelength anomalous diffraction data set of HDAC6 ZnF-
UBP domain was collected at 100 K on BNL Beamline X29 with
wavelength of 1.26 Å. The HDAC6 ZnF-UBP with peptide
RLRGG data were collected on a Rigaku FR-E super bright
rotating anode x-ray generator. Program HKL2000 was used for
both data processing and scaling. The HDAC6 ZnF-UBP struc-
ture was determined using the anomalous signal from native-
bound zinc atoms at 1.26 Å. The program SOLVE was used to
search the zinc sites, and RESOLVE was used to perform the
site refinement and initial model building. ARPwARP was used
for model building. The graphics program COOT (17) was used
for manual model refinement and visualization. Refmac5 was
also used to refine the model. The structure of HDAC6 with
RLRGG peptide was determined using HDAC6 (3C5K) as a
molecular replacement model. Diffraction data on HDAC6
with ubiquitin complex structure was collected on the APS
beamline 23ID-B, and the structure was determined using the
HDAC6 (3C5K) structure as a model. The program BUSTER
(18) was used for structural refinement.

Pulldown Assay and Dynamic Light Scattering (DLS)—Pro-
itoms of interest (one of the interacting proteins was His-tagged)
at 1 mg/ml in buffer A were incubated at room temperature for
30 min allowing for batch binding before either Ni-NTA (Qia-
gen) or Talon (Clontech) was added. The resin was washed
extensively prior to elution with SDS-PAGE loading buffer.
Eluted proteins were analyzed using NuPAGE 4–12% Bis-Tris
gels (Invitrogen). For DLS experiments, equimolar amounts of
HDAC6 Zn-UBP domain and ubiquitin or ubiquitin mutants
were incubated together at room temperature for 30 min before
centrifugation at 13,000 rpm for 10 min. The final protein con-
centration was determined using the Bradford protein assay
(Bio-Rad). The samples were then transferred into 384-well
plates for DLS analysis. DLS data were recorded using DynaPro
Plate Reader with Dynamics software (Wyatt Technology).

Immunoprecipitation—293T cells were transfected with
GFP-CFTRΔ508 using Lipofectamine 2000 (Invitrogen). At
48 h post-transfection, the cells were treated with either Me6SO
or MG132 (EMD Biosciences). After 16 h of treatment, the cells
were lysed, and proteins were quantified. Subsequently, 1 mg of total protein lysate/condition was incubated overnight with 50 μg of recombinant peptide at 4 °C before immunoprecipitation with 10 μg of GFP antibody/sample using protein A-agarose beads (Invitrogen). For ataxin-3 knockdown experiments, 293T cells were transfected with ataxin-3-specific siRNA (ON_TARGETplus SMARTpool ATXN3 L-012013-00-0005; Dharmacon RNAi Technologies) or scramble control siRNA (ON-TARGETplus nontargeting pool D-001810-10-05; Dharmacon RNAi Technologies), using Dharmafect transfection reagent according to the manufacturer’s instructions. After 24 h post-transfection, these cells were transfected with GFP-CFTRΔ508, GFP-Atx1-82Q, or GFP and treated as described above.

Western Blot Analysis—Proteins were extracted from cells with a lysis buffer (50 mM Tris, pH 7.5, 150 mM KCl, 1 mM PMSF, 1% Triton, protease inhibitor mixture (Sigma)). Protein concentrations were measured using the Bradford protein assay (Bio-Rad). Sample lysates were resolved by SDS-PAGE and probed with anti-GFP 1:2000, anti-ataxin3 1:1000, anti-HDAC6 1:1000, anti-C-terminal ubiquitin 1:1000, and anti-N-terminal ubiquitin 1:1000. Western blot analysis was performed by incubating with the infrared dye-conjugated secondary antibodies, IR700 and IR800 (LI-COR Biosciences) for 1 h at room temperature; blots were imaged and processed on an Odyssey® infrared imaging system.

Immunofluorescence and Image Acquisition and Processing—Cultured A549 or 293T cells were transfected with respective plasmids and fixed post-treatment with PBS with 3.5% formaldehyde for 15 min and washed in PBS with 0.4% Triton X-100. The cells were blocked in 5% goat serum (in PBS) for 1 h before incubating in appropriate primary antibody mixtures with mild shaking at 4 °C overnight. Primary antibody dilutions used included anti-C-terminal ubiquitin antibody 1:250, anti-ataxin-3 antibody 1:250, anti-HDAC6 antibody 1:1000, anti-USP5 antibody 1:250, anti-USP13 antibody 1:250, and secondary antibodies conjugated to Alexa 555 or Alexa 647 were used at 1:250. All of the antibody incubations were performed at 4 °C overnight in the presence of 5% normal goat serum. Fluorescence images were acquired on Olympus FX1000 confocal microscope and processed using FluoView10ASW (Olympus). The figure panels were assembled using Adobe Photoshop CS4.

RESULTS

HDAC6 ZnF-UBP Domain Interacts with Polyubiquitinated Protein Aggregates—An earlier report showed that HDAC6 binds polyubiquitinated protein aggregates through its ZnF-UBP domain (11). However, because typical ZnF-UBP domains only bind unanchored ubiquitin C termini (19) and all the C termini of ubiquitin moieties in polyubiquitinated proteins are conjugated either to protein substrate or other ubiquitin moieties (20), it has been suggested that the ZnF-UBP domain may play a regulatory role rather than bind directly to the aggregates (12). To examine the direct interaction between HDAC6 ZnF-UBP domain and protein aggregates, we used the mutant cystic fibrosis transmembrane conductance regulator CFTR-ΔF508-induced protein aggregation as a model (3, 11). Cultured 293T cells were transfected with GFP-CFTR-ΔF508 and treated with a proteasome inhibitor, MG132, to induce aggresome formation. The interaction between HDAC6 and aggregates was tested by incubating cell lysates with recombinant HDAC6 ZnF-UBP domain. The binding activity of the recombinant HDAC6 ZnF-UBP domain to ubiquitin was first tested and confirmed by an in vitro pull down assay. As shown in Fig. 1A, when incubated with ubiquitin, His-tagged HDAC6 ZnF-UBP pulled down ubiquitin in a manner similar to the His-tagged UBP domain of USP5, a known ubiquitin-binding protein (13). We generated an active site mutant R1155A/Y1184A based on homologue analysis (12, 13). Although the HDAC6 ZnF-UBP domain recruit protein aggregates via ubiquitin C termini.
C-terminal diglycine motif is necessary for binding to HDAC6 ZnF-UBP.

To reveal the structural details of this interaction, we solved the crystal structures of the ZnF-UBP domain of HDAC6 and its complexes with either full-length ubiquitin or a ubiquitin C-terminal peptide (Table 1). The crystal structure of the HDAC6 ZnF-UBP domain (residues 1109–1215), determined at 1.55 Å resolution using anomalous signals from natively
HDAC6 Recruits Protein Aggregates via Ubiquitin C Termini

HDAC6 + peptide RLRGG

Crystallographic data collection and phasing statistics

| Protein Data Bank code | HDAC6 | HDAC + peptide RLRGG | HDAC6 + ubiquitin |
|------------------------|-------|----------------------|------------------|
| Space group            | P₂₁₂₁₂₁ | P₂₁₂₁₂₁ | P₄₁₂₂ |
| Unit cell              | a = 40.3 Å, b = 45.1 Å, c = 55.8 Å | a = 31.7 Å, b = 36.1 Å, c = 89.0 Å | a = 133.7 Å, c = 118.8 Å |
| Resolution             | 3.05 Å | 1.72 Å | 3.0 Å |
| Completeness (%)       | 98.0% | 94.9% | 100% |
| Rmerge (%)             | 17.3/22.7 | 17.4/23.0 | 23.5/26.5 |
| Root mean square deviation | 0.008 | 0.010 | 0.01 |
| Bond length            | 1.15 Å | 1.19 Å | 1.12 Å |
| Bond angle             | 10.9 Å | 22.0 Å | 72.9 Å |
| Molprobity Ramachandran plot | 97.2% | 96.0% | 93.98% |
| Allowed (%)            | 100% | 100% | 99.8% |
| Outliers (%)           | 0% | 0% | 1% |

*apo-structure was collected at peak zinc wavelength.

**Rsym = sum(|I − <I>|)/sum(<I>), where I is the observed intensity, and <I> is the average intensity from multiple observations of symmetry-related reflections.

†Rfree value was calculated with ~5% of the data.

bound Zn²⁺ ions, revealed a compact structure consisting of five anti-parallel β-strands, two α-helices, and three Zn²⁺ ions (Fig. 2A). A distinct pocket was visible on the surface, formed by a cluster of aromatic residues (Fig. 2A). The ZnF-UBP domain of HDAC6 has similar folds overall to those of USP5 (Protein Data Bank code 2G43) and USP16 (Protein Data Bank code 2G45). However, HDAC6 ZnF-UBP lacks the additional USP5 ZnF-UBP and ubiquitin complex (Protein Data Bank code 2G45). However, HDAC6 ZnF-UBP lacks the additional contacts that USP5 ZnF-UBP makes with the globular surface of ubiquitin (13). Our structural studies therefore demonstrate that the HDAC6 ZnF-UBP domain binds ubiquitin by recognizing the unanchored C-terminal tail, with the vast majority of the interactions made exclusively through the C-terminal diglycine motif. This domain makes no specific interaction with ubiquitin side chains beyond the C-terminal tail; indeed, the ubiquitin residues beyond the diglycine motif became increasingly “mobile” as indicated by their crystallographic B-factors (Fig. 2E).

Polyubiquitinated Protein Aggregates Contain Unanchored Ubiquitin C Termini—So far, our work has indicated that HDAC6 ZnF-UBP specifically recognizes ubiquitin C terminus and is capable of binding protein aggregates. This result further suggests that HDAC6 ZnF-UBP interacts with protein aggregates exclusively through unanchored ubiquitin C termini in the aggregates and not through binding polyubiquitinated proteins directly. To detect the presence of unanchored ubiquitin C terminus in protein aggregates, we used a ubiquitin C terminus-specific antibody (anti-UbiC) to probe the immunoprecipitated aggregates resolved by SDS-PAGE. The specificity of the anti-UbiC antibody was confirmed by Western analysis (Fig. 3A) in which the antibody detected free ubiquitin C-terminal in pure mono- and tetraubiquitin peptides but only poorly detected the C-terminal AFC-conjugated ubiquitin. The low yet visible signal was likely due to contamination by a trace amount of unconjugated mono-ubiquitin, as seen from mass spectrometry analysis of the commercial ubiquitin-AFC sample (supplemental Fig. S3). AFC-conjugated ubiquitin appears as a peak at 8776 Da in the mass spectrum; however, we also
detected a peak at 8565 Da that corresponds to unmodified ubiquitin with an unconjugated C terminus. This trace amount of unconjugated ubiquitin contributed to the low signal detected by the anti-UbiC antibody. When the same AFC-conjugated fraction was probed with an antibody specific for the ubiquitin N terminus (anti-UbiN), a robust signal was shown (Fig. 3B), suggesting that the anti-UbiC antibody recognized ubiquitin C-terminal with high preference. To further examine the specificity of anti-UbiC antibody, we probed various ubiquitin mutants with C-terminal truncations or point mutations with anti-UbiC and anti-UbiN antibody. As shown in Fig. 3C, anti-UbiN antibody could recognize all the peptides (Fig. 3C, upper panel); however, anti-UbiC antibody failed to recognize Ub71, where the last five amino acids were missing, and only

FIGURE 2. The structures of HDAC6 ZnF-UBP domain and its complexes with ubiquitin and RLRGG peptide. A, ribbon diagram of HDAC6 ZnF-UBP domain. The residues in the ubiquitin-binding site are shown in cyan. B, overlay of structures of HDAC6 ZnF-UBP domain (shown in ribbon representation) in complex with ubiquitin (yellow sticks) and RLRGG peptide (cyan sticks). C, structures of HDAC6 ZnF-UBP domain and its complex with RLRGG peptide, showing the ubiquitin binding pocket of HDAC6 ZnF-UBP domain. The last three residues of the peptide (RGG) are shown as sticks. D, overlay of the ubiquitin-binding site of HDAC6 ZnF-UBP (green) and its complex with RLRGG peptide (cyan). The peptide is shown in gray. The different conformations of Arg-1155 and Tyr-1156 can be clearly observed. E, the complex structure of HDAC6-UBP and RLRGG peptide, showing the hydrogen bond network. The peptide is colored by B-factors. The water molecules are shown in red. F, overlay of structures of HDAC6 ZnF-UBP (cyan) and its complex with RLRGG peptide (green), showing that minimal change occurred in the overall protein fold upon peptide binding. The protein is shown in ribbon representation, and the peptide is shown as sticks (yellow).
poorly recognized the other truncated (Ub74) or mutant (G75A/G76A) ubiquitin peptides (Fig. 3C, lower panel). Collectively, these experiments demonstrated the specificity of the ubiquitin C-terminal (anti-UbiC) antibody.

Next, we used the anti-UbiC antibody to detect the presence of unanchored ubiquitin in aggregates in cultured cells. When GFP-CFTR ΔF508 mutant protein aggregates formed in cultured 293T cells were pulled down with an anti-GFP antibody, a significant amount of unanchored mono- and polyubiquitin (oligomeric-ubiquitin and higher molecular weight ubiquitins) were detected by anti-UbiC antibody (Fig. 3E, lanes 1–3), and the level of unanchored ubiquitin from mono- and polyubiquitin was enhanced with MG132 treatment (Fig. 3E, lanes 4–6), confirming the presence of unanchored ubiquitin C termini in protein aggregates. Note that the results pertaining to lanes 7–12 in Fig. 3E will be described in the following section. Next, we used the anti-UbiC antibody to examine the distribution of ubiquitin C termini in cells. To achieve better resolution, we used A549 cells for their larger cell morphology and compared their protein distribution with 293T cells. In untransfected A549 cells or 293T cells (supplemental Fig. S4), unconjugated ubiquitin C termini were evenly distributed throughout the cells without significant clustering (supplemental Fig. S4, A2 and B2). Expression of GFP-CFTR ΔF508 caused protein aggregation (Fig. 4B, and supplemental Fig. S4, C and D). Unanchored ubiquitin C termini were detected in small clusters of...
GFP-CFTR-ΔF508 (supplemental Fig. S4, C2) and in large and perinuclear aggregates of GFP-CFTR-ΔF508 upon MG132 treatment, indicative of aggresome formation (Fig. 4, B and D, and supplemental Fig. S4, D2). Ubiquitin C termini were also detected in perinuclear clusters in MG132-treated cells that were not transfected with CFTR (supplemental Fig. S4, D2', arrowheads), suggesting aggresome formation upon ubiquitin proteasome blockage in normal/untransfected cells. These results further confirm the presence of unanchored ubiquitin C termini in protein aggregates that can be accessed by the antibody.

**Unanchored Ubiquitin C Termini Are Exposed by Deubiquitinase Ataxin-3** — It has been reported that HDAC6 is involved in aggresome formation of only polyubiquitinated proteins, but not nonubiquitinated proteins, such as GFP-250 aggregates (11). Therefore, it is likely that unanchored ubiquitin tails are generated in situ from polyubiquitinated proteins by a deubiquitinase associated with aggregate particles. Among known deubiquitinases, ataxin-3 has been shown to interact with polyubiquitinated proteins (23) and to be involved in aggresome formation without a known role (24, 25). We therefore examined the presence and localization of ataxin-3 during

| GFP-CFTR | Ataxin-3 | Ub C-term | DAPI | MERGE |
|----------|----------|-----------|------|-------|
| DMSO     |          |           |      |       |
|          | A1       | A2        | A3   | A4    | A5    |
| MG132    |          |           |      |       |
|          | B1       | B2        | B3   | B4    | B5    |
| Scrambled RNAi | |           |      |       |
| Ataxin3 RNAi | |           |      |       |
|          | C1       | C2        | C3   | C4    | C5    |
| MG132    |          |           |      |       |
|          | D1       | D2        | D3   | D4    | D5    |
| Scrambled RNAi | |           |      |       |
| Ataxin3 RNAi | |           |      |       |
|          | E1       | E2        | E3   | E4    | E5    |

**FIGURE 4. Unanchored ubiquitin was co-localized with ataxin-3 in CFTR-ΔF508 aggregates.** A549 cells expressing GFP-CFTR-ΔF508 were transfected with either scrambled RNAi (A, B, and D) or ataxin-3 RNAi (C and E) and treated with either Me2SO (DMSO, A) or MG132 (B–E). The cells were labeled for GFP (green), ataxin-3 (red), C-terminal ubiquitin (Ub C-term, magenta in A–C), HDAC6 (magenta in D and E), and DAPI (blue). Perinuclear areas in B1 and D1 (white boxes) are shown in B' and D', respectively. The ataxin-3 siRNA-mediated knockdown efficiency varied among cells, because we observed that some cells have efficient knockdown (arrow in E), whereas other cells have significant residual levels of ataxin-3 (arrowhead in E). Scale bars, 10 μm.
aggresome formation using an ataxin-3-specific antibody (26–28). As shown in Fig. 3H, ataxin-3 was co-immunoprecipitated with GFP-CFTR-ΔF508 aggregates upon MG132 treatment, confirming that ataxin-3 is associated with aggregates (Fig. 3H, lanes 3 and 6). In unstressed cells, ataxin-3 was evenly distributed (Fig. 4, A2, and supplemental Fig. S4, A3) as previously reported (29). Upon MG132 treatment, ataxin-3 co-localized with GFP-CFTR-ΔF508 clusters and unanchored ubiquitin C termini (Fig. 4B and supplemental Fig. S4, D2 and D2’). To test whether ataxin-3 is required for producing unanchored ubiquitin C termini in protein aggregates, we performed ataxin-3 siRNA knockdown experiments. Using siRNA transfection-mediated knockdown, we were able to reduce the cellular ataxin-3 level to less than 27% of the normal level (supplemental Fig. S5). Consequently, the level of ataxin-3 associated with aggregates was reduced (Fig. 3H, lanes 9 and 12). In ataxin-3 knockdown cells, GFP-CFTR-ΔF508 showed a diffuse signal, indicating that aggresome formation was hindered (Fig. 4E and supplemental Fig. S4F). Although unanchored ubiquitin C termini were detected in knockdown cells, their co-localization with GFP-CFTR-ΔF508 was not observed, suggesting a lack of unanchored ubiquitin C termini in GFP-CFTR-ΔF508 aggregate particles. The importance of ataxin-3 in aggresome formation is further shown in Fig. 4E, where ataxin-3 knockdown in one of the cells was not efficient, leaving a significant amount of ataxin-3 to enable CFTR-ΔF508 aggresome formation (Fig. 4E, arrowhead). In contrast, a neighboring cell with efficient ataxin-3 knockdown failed to form aggresomes.

The reduced amount of unanchored ubiquitin C-terminal further was demonstrated by the Western analysis, in which the level of ubiquitin C termini associated with GFP-CFTR-ΔF508 aggregates in ataxin-3 siRNA-treated cells was reduced (Fig. 3E, lanes 9 and 12). Specifically, the amount of low molecular weight oligomeric ubiquitin and mono-ubiquitin with free C termini pulled down with aggresomes was significantly reduced (Fig. 3E, compare lanes 3 and 6 with lanes 9 and 12). However, the signal for high molecular weight ubiquitin chains was indistinguishable among lanes 3, 6, 9, and 12 because the anti-UbiC antibody did not recognize conjugated C termini present in the higher molecular weight ubiquinated protein aggregates. To rule out the possibility that ataxin-3 siRNA treatment affected the expression of GFP-CFTR-ΔF508, we determined the protein level of GFP-CFTR-ΔF508 in siRNA-treated cells, and as shown in supplemental Fig. S6, the total level of GFP-CFTR-ΔF508 expressed in siRNA-treated cells was not affected by ataxin-3 knockdown. Furthermore, the amount of immunoprecipitated GFP-CFTR-ΔF508 was not affected by siRNA treatment, because similar amounts of GFP-CFTR-ΔF508 were precipitated with or without ataxin-3 knockdown (Fig. 3D). Interestingly, the amount of HDAC6 associated with GFP-CFTR-ΔF508 aggregates was reduced in ataxin-3 siRNA-treated cells (Fig. 3G, lanes 9 and 12), indicating that the interaction between HDAC6 and protein aggregates is dependent on the presence of exposed ubiquitin C termini generated by ataxin-3. To further confirm that the effect of ataxin-3 was restricted to generating unconjugated free C termini in the aggregates, we probed the aggregates pulled down with or without ataxin-3 knockdown with an antibody specific for ubiquitin N termini (anti-UbiN). As shown in Fig. 3B, anti-UbiN antibody robustly recognizes the ubiquitin C terminus, where the C termini are capped by AFC conjugate. With anti-UbiN antibody, we show that altering ataxin-3 levels did not affect the levels of ubiquitin moieties expressed in cells (Fig. 3F, compare input lanes 1 and 7, and lanes 4 and 10) or pulled down in the aggregates (Fig. 3F, comparing lanes 3 and 9 and lanes 6 and 12), suggesting that ataxin-3 knockdown did not reduce the total level of ubiquitin expressed in cells or the ubiquitin associated with protein aggregates but only specifically reduced the amount of unanchored ubiquitin C termini in protein aggregates. We further confirmed these observations using a different ubiquitinated protein substrate, human ataxin-1-82Q-GFP, which is known to form aggregates in cells when treated with MG132 (30). We transfected 293 cells with ataxin-1-82Q-GFP, treated with MG132 to induce aggregate formation, and siRNA to knock down ataxin-3. Similar to the results with GFP-CFTR-ΔF508 aggregates, we found that in ataxin-3 siRNA-treated cells, ataxin-3 levels were significantly reduced (supplemental Fig. S7E, lanes 7–12), there was a reduction of ubiquitin C termini (supplemental Fig. S7B), and ataxin-1-82Q-GFP failed to recruit HDAC6 (supplemental Fig. S7D, lanes 9 and 12). Collectively, these results support the notion that HDAC6 requires the unanchored ubiquitin C termini generated by ataxin-3 to interact with protein aggregates.

USP5 and USP13 are two known deubiquitinases with a specialized ZnF-UBP domain that recognizes the C-terminal diglycine motif in unattached chains (13, 31, 32). We examined the cellular distribution of these two well-characterized deubiquitinases and found that neither of them co-localized with CFTR-ΔF508 aggresomes (supplemental Fig. S8), suggesting that they are unlikely to be involved in aggresome formation. This observation supports a specific role for deubiquitinase ataxin-3 in aggresome formation. Collectively, our results suggest a novel mechanism of ataxin-3-mediated HDAC6-dependent aggresome formation, where the aggregate-specific deubiquitinase, ataxin-3, cleaves (poly)ubiquitin moieties in polyubiquitinated proteins to expose their C-terminal diglycine motifs, providing a handle for HDAC6 binding and subsequent transport to the aggresome.

DISCUSSION

Our x-ray crystallography and biochemical results indicated that the HDAC6 ZnF-BUZ domain binds unconjugated diglycine motif at the C terminus of ubiquitin to promote aggresome formation. Using cellular analyses, we further showed that ataxin-3 is the deubiquitinase that generates the unanchored ubiquitin C termini in protein aggregates. The exposed ubiquitin C-terminal tails serve as “tags” for HDAC6 recognition and subsequent transport to the aggresome. Our work provides a critical piece of the mechanism underlying HDAC6-mediated aggresome formation (Fig. 5), where aggregate-associated ataxin-3 deubiquitinase cleaves polyubiquitin chains and exposes unanchored ubiquitin C termini for HDAC6 recognition of aggregate particles and their subsequent transport to form aggresomes.

Previous work has suggested that HDAC6 binds protein aggregates via direct interactions with the polyubiquitin moiety through its ZnF-UBP domain (11). Our work indicates that such direct binding of HDAC6 to polyubiquitinated proteins is
not feasible, because ubiquitin moieties are conjugated to protein substrates through C-terminal diglycine motifs (14). All known ZnF-UBP domains have been shown to bind unanchored ubiquitin or ubiquitin chains. HDAC6 recognizes and binds these unanchored ubiquitin C-terminal tails in protein aggregates and recruits them to dynein motor complexes that subsequently transport the aggregated cargo to the aggresomes.

Protein aggregates need to be sequestered by aggresomes to avoid cytotoxicity. It is believed that protein aggregates are recruited to aggresomes by HDAC6. However, it has remained mysterious how scattered protein aggregates are recognized by HDAC6. Our biochemical, cellular, and imaging evidence unambiguously showed that the unconjugated ubiquitins are integrated parts of protein aggregates. These unconjugated ubiquitin tails are solvent-accessible on the surface of the aggregates, which can interact with HDAC6 ZnF-UBP domain or anti-UbiC antibody (Fig. 3). We provided evidence that unanchored ubiquitin chains with various lengths are presented in protein aggregates (Figs. 3 and 4), serving as “tags” for HDAC6 to recognize and bind. When the proteasome function is disrupted, ubiquitin is no longer “recycled” efficiently, which may deplete the free ubiquitin pool in the cytoplasm (33). The exposed unanchored ubiquitin C termini on protein aggregates thus act as “signals” for HDAC6 recognition. However, it remains unclear how the unanchored mono- or polyubiquitin chains are retained within protein aggregates without diffusing away.

An intriguing question is how the unanchored ubiquitin tails are exposed in aggregates. It has been shown that the ubiquitinase ataxin-3 is required for aggresome formation (24, 25), but it was unclear why the de ubiquitination activity is essential for this process. Although the exact de ubiquitination mechanism of ataxin-3 has yet to be fully elucidated, several reports have suggested that ataxin-3 is a polyubiquitin-editing enzyme that could cut within ubiquitin chains in polyubiquitinated proteins (23, 34). Our results show that ataxin-3 is one of the deubiquitinas responsible for exposing unanchored C termini on the aggregates. RNAi-mediated knockdown of ataxin-3 significantly reduces the amount of unanchored ubiquitin chains, which in turn eliminates HDAC6 binding (Fig. 3E). Therefore, our model defines an essential role for ataxin-3 deubiquitination activity in aggresome formation.

In summary, our structural, biochemical, and cellular analyses demonstrate that the ZnF-UBP domain of HDAC6 binds unconjugated C-terminal diglycine motifs of ubiquitin and that this interaction is important for the binding and transport of polyubiquitinated protein aggregates. Aggresome formation is also dependent on ataxin-3, which is known to cleave polyubiquitin chains and to likely expose unanchored ubiquitin C termini for HDAC6 recognition of aggregate particles. Although proteins targeted for proteasome degradation are covalently tagged by ubiquitin through isopeptide linkages, our findings suggest that protein aggregates targeted for aggresomal clearance are tagged noncovalently by unanchored ubiquitin C termini.

The aggresome pathway has emerged as a potential therapeutic target for cancer treatment (35, 36). Our studies suggest the ZnF-UBP domain of HDAC6 as a site of interest. The deep and hydrophobic C-terminal ubiquitin-binding site of HDAC6 represents an attractive site for the development of small molecule antagonists.
Acknowledgments—We thank Drs. James E. Bradner, Brian Raught, Aled Edwards, Dalia Barsyte, and Brant Watson for critically reviewing the manuscript.

REFERENCES

1. Goldberg, A. L. (2003) Nature 426, 895–899
2. Tai, H. C., and Schuman, E. M. (2008) Nat. Rev. Neurosci. 9, 826–838
3. Johnston, J. A., Ward, C. L., and Kopito, R. R. (1998) J. Cell Biol. 143, 1883–1898
4. Garcia-Mata, R., Gao, Y. S., and Sztul, E. (2002) Traffic 3, 388–396
5. Chin, L. S., Olzmann, J. A., and Li, L. (2010) Biochem. Soc. Trans 38, 144–149
6. Lee, J. Y., Koga, H., Kawaguchi, Y., Wong, E., Gao, Y. S., and Yao, T. P. (2010) EMBO J. 29, 969–980
7. Pandey, U. B., Nie, Z., Batlevi, Y., McCray, B. A., Ritson, G. P., Nedelsky, N. B., Schwartz, S. L., DiProspero, N. A., Knight, M. A., Schuldiner, O., Padmanabhan, R., Hild, M., Berry, D. L., Garza, D., Hubbert, C. C., Yao, T. P., Baehrecke, E. H., and Taylor, J. P. (2007) Nature 447, 859–863
8. Matthias, P., Yoshida, M., and Khochbin, S. (2008) Cell Cycle 7, 7–10
9. Valenzuela-Fernández, A., Cabrero, J. R., Serrador, J. M., and Sánchez-Madrid, F. (2008) Cell Cycle 7, 7–10
10. Dompierre, J. P., Godin, J. D., Charrin, B. C., Cordelières, F. P., King, S. J., Humbert, S., and Saudou, F. (2007) J. Neurosci 27, 3571–3583
11. Kawaguchi, Y., Kovacs, J. I., McLaurin, A., Vance, J. M., Ito, A., and Yao, T. P. (2003) Cell 115, 727–738
12. Pai, M. T., Tzeng, S. R., Kovacs, J. I., Keaton, M. A., Li, S. S., Yao, T. P., and Zhou, P. (2007) J. Mol. Biol. 370, 290–302
13. Reyes-Turcu, F. E., Horton, J. R., Mullally, I. E., Heroux, A., Cheng, X., and Wilkinson, K. D. (2006) Cell 124, 1197–1208
14. Finley, D., and Chau, V. (1991) Annu. Rev. Cell Biol. 7, 25–69
15. Hicke, L., Schubert, H. L., and Hill, C. P. (2005) Nat. Rev. Mol. Cell Biol. 6, 610–621
16. Raiborg, C., Slagsvold, T., and Stenmark, H. (2006) Trends Biochem. Sci. 31, 541–544
17. Emsley, P., and Cowtan, K. (2004) Acta Crystallogr. 49, 37–60
18. Bonnet, J., Romier, C., Toru, L., and Devys, D. (2008) Trends Biochem. Sci. 33, 369–375
19. Hochstrasser, M. (1996) Annu. Rev. Genet. 30, 405–439
20. Boyault, C., Gilquin, B., Zhang, Y., Rybin, V., Garman, E., Meyer-Klaucke, W., Matthias, P., Müller, C. W., and Khochbin, S. (2006) EMBO J. 25, 3357–3366
21. Burnett, B., Li, F., and Pittman, R. N. (2003) Hum. Mol. Genet. 12, 3195–3205
22. McDonald, K. M., Li, W., Ching, K. A., Batalov, S., Tsai, C. C., and Joazeiro, C. A. (2003) Proc. Natl. Acad. Sci. U.S.A. 100, 8892–8897
23. Menzies, F. M., Huebener, J., Renna, M., Bonin, M., Riess, O., and Rubinsztein, D. C. (2010) Brain 133, 93–104
24. Paulson, H. L., Perez, M. K., Trotter, Y., Trojanowski, J. Q., Subramony, S. H., Das, S. S., Vig, P., Mandel, J. L., Fischbeck, K. H., and Pittman, R. N. (1997) Neuron 19, 333–344
25. Trotter, Y., Cancel, G., An-Gourfindel, I., Lutz, Y., Weber, C., Brice, A., Hirsch, E., and Mandel, J. L. (1998) Neurobiol. Dis. 5, 335–347
26. Pozzi, C., Valforta, M., Tedeschi, G., Galbusera, E., Pastorl, V., Bigi, A., Nonnis, S., Grassi, E., and Fusl, P. (2008) Neurobiol. Dis. 30, 190–200
27. Zhai, R. G., Zhang, F., Hiesinger, P. R., Cao, Y., Haueter, C. M., and Bellen, H. J. (2008) Nature 452, 887–891
28. Amerik, A., Swaminathan, S., Krantz, B. A., Wilkinson, K. D., and Hochstrasser, M. (1997) EMBO J. 16, 4826–4838
29. Komander, D., Clague, M., and Urbé, S. (2009) Nat. Rev. Mol. Cell Biol. 10, 550–563
30. Mimnaugh, E. G., Chen, H. Y., Davie, J. R., Celis, J. E., and Neckers, L. (1997) Biochemistry 36, 14418–14429
31. Mao, Y., Senic-Matuglia, F., Di Fiore, P. P., Polo, S., Hodson, M. E., and de Camilli, P. (2005) Proc. Natl. Acad. Sci. U.S.A. 102, 12700–12705
32. Olzmann, J. A., Li, L., and Chin, L. S. (2008) Curr. Med. Chem. 15, 47–60
33. Rodriguez-Gonzalez, A., Lin, T., Ikeda, A. K., Simms-Waldrip, T., Fu, C., and Sakamoto, K. M. (2008) Cancer Res. 68, 2557–2560